QUEST DIAGNOSTICS INC 4

SVP Karthik Kuppusamy reported an exempt purchase of 37 shares of Quest Diagnostics Inc. common stock via dividend reinvestment/plan acquisitions, increasing his direct holdings to 13,557 shares.

On July 22, 2026, Karthik Kuppusamy, SVP, Clinical Solutions of Quest Diagnostics Inc., reported an exempt acquisition of 37 shares of common stock at an average price of approximately $206.81 per share, totaling about $7,649, primarily reflecting automatic dividend reinvestment and purchases under the company’s stock purchase plan. Following this transaction, he directly owned 13,557 shares, in addition to 358 shares held indirectly in a trust and 1,691 shares held through the company’s 401(k) plan, bringing his total beneficial ownership to 15,606 shares. Based on the current market price of about $230.39 per share, his aggregate holdings are valued at roughly $3.6 million. The filing notes that these are routine, exempt purchases (eligible for deferred Form 5 reporting) that the insider chose to disclose early, indicating ongoing participation in company share accumulation programs rather than a discretionary open‑market trade.

Filing Facts

CIK

1022079

Ticker

DGX

Form

4

Source Type

sec

Accession

0001022079-26-000086

Alert Tier

4